Table 1 Characteristics of the 5 source studies used in these analyses.
Primary reference | Primary outcomes | Study drugs | N | Mean modal dose (mg/day [SD]) | Study duration (weeks) | Diagnoses | Other baseline inclusion criteria |
|---|---|---|---|---|---|---|---|
Tran [13] | Efficacy Safety | Olanzapine Risperidone | 172 167 | 17.2 (3.6) 7.2 (2.7) | 28 | Schz, Schzfm, Schzaff | Inpatient and outpatient Age 18 to 65 BPRS (ext) score ≥ 42 |
Kinon [14] | Negative Symptoms Functional Outcome Efficacy Safety | Olanzapine Quetiapine | 171 175 | 15.6 (4.3) 455.8 (156.3) | 24 | Schz, Schzaff | Outpatients Age 18 to 65 Score ≥ 4 on at least 3, or ≥ 5 on at least 2 of the 7 negative symptom items of the PANSS, and ≥ 60 (moderate difficulties) on the GAF. |
Breier [17] | Efficacy Safety | Olanzapine Ziprasidone | 277 271 | 15.3 (4.5) 116.0 (39.9) | 28 | Schz | Inpatient and outpatient Age 18 to 75 Scores ≥ 42 on the BPRS (ext), ≥ 4 on at least one positive symptom item of the PANSS, and ≥ 4 on the severity of illness subscale of the CGI |
Kinon [16] | Depressive Symptoms Efficacy Safety | Olanzapine Ziprasidone | 202 192 | 14.2a 110.2a | 24 | Schz, Schzaff | Inpatient and Outpatient Age 18 to 60 Scores ≥ 16 (mild depression) on the MADRS and ≥ 4 (pervasive feelings of sadness or gloominess) on item 2 (reported sadness) of the MADRS |
Kane [15] | Efficacy Safety | Olanzapine Aripiprazole | 281 285 | 16.7 (2.4) 19.3 (6.8) | 28 | Schz | Initial PANSS Total score of ≥ 75, a minimum score of ≥ 4 on one of the PANSS positive, and a minimum score of 4 on the CGI-S at both visits 1 (screening) and 2 (randomization), with an initial score of ≥ 3 on the CGI-I at visit 2. |